Table 1.
Disease characteristics of the study population.
| Characteristic | Psoriatic arthritis n = 59 | Axial spondyloarthritis n = 95 | Total n = 154 |
|---|---|---|---|
| Age, mean (SD) | 51 (12) | 47 (10) | 49 (11) |
| Male | 27 (46) | 58 (61) | 85 (55) |
| Disease duration, m (SD) | 7 (8) | 6 (5) | 6 (7) |
| Number of previous biologics, median (IQR) | 3 (2) | 3 (2) | 3 (2) |
| csDMARD prior to SEC | 39 (66) | 15 (16) | 54 (36) |
| Type of csDMARD | |||
| Methotrexate | 34 (58) | 10 (11) | 44 (29) |
| Leflunomide | 9 (15) | 3 (3) | 12 (8) |
| Sulfasalazine | 1 (2) | 5 (5) | 6 (4) |
| Other | 3 (5) | 1 (1) | 4 (3) |
| Glucocorticoids | 18 (31) | 10 (11) | 28 (19) |
| Secukinumab dose 300 mg | 34 (57) | 11 (12) | 45 (29) |
| Obesity (BMI > 30) | 16 (27) | 10 (11) | 26 (17) |
| Smoker | 15 (26) | 29 (31) | 44 (29) |
| Hypertension | 17 (29) | 18 (19) | 35 (23) |
| Dyslipidemia | 22 (37) | 19 (20) | 41 (27) |
| Diabetes | 9 (15) | 3 (3) | 12 (8) |
| COPD | 1 | - | 1 |
| Cardiovascular disease* | 1 | 2 | 3 (2) |
| Ischemic heart disease | 4 (7) | 3 (3) | 7 (5) |
| Depression | 10 (17) | 17 (18) | 27 (18) |
| Chronic Kidney Disease | 2 | - | 2 |
| Hepatic failure | 1 | 2 | 3 (2) |
Cells include n (%) unless otherwise indicated.
*
Myocardial infarction or cerebrovascular event.
SD, standard deviation; IQR, interquartile range; csDMARD, conventional synthetic disease modifying anti-rheumatic drug; BMI, body mass index; COPD, Chronic obstructive pulmonary disease.